Omalizumab and the World Health Organization. It is also used to treat people 12 years and above with chronic spontaneous urticaria (also called chronic idiopathic urticaria), which cannot be treated with elevated doses of H1-antihistamines. The main adverse effect is anaphylaxis (a life-threatening systemic allergic reaction), with a rate of occurrence of 1 to 2 patients per 1,000. Like other protein and antibody drugs, omalizumab also causes anaphylaxis, although at a relatively low frequency among antibody drugs. The allergic reaction is probably not due to the binding characteristics of the antibody drug, but to the protein nature of the antibody. The
Allergic transfusion reaction from a donor who has allergies, followed by antigen exposure. An allergic transfusion reaction is a type of transfusion reaction that is defined according to the Center for Disease Control (CDC) as: An allergic transfusion reaction is diagnosed if two or more of the following occur within 4 hours of cessation of transfusion: A probable diagnosis results if any one of the following occurring within 4 hours of cessation of transfusion: Treatment of an allergic transfusion reaction is to immediate stop the transfusion. If the only symptoms are mild (i.e., hives and itching), the patient may be treated with an